Loading
Bleomycin is the 'B' in BEP for testicular cancer and ABVD for Hodgkin lymphoma; its unique danger is scarring of the lungs, so lung function is monitored and it is often dropped when safe.
Approved 1973. BEP (testicular; omitted in EP for good-risk patients with lung risk), ABVD (Hodgkin; omitted after negative interim PET in RATHL), Kaposi sarcoma (bleomycin-vincristine in Africa), sclerotherapy of lymphatic malformations and pleurodesis, electrochemotherapy for cutaneous tumours. Cumulative dose limit ~400 units; pulmonary toxicity 10%, fatal in 1-2%.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Chelates iron and generates free radicals that cause single- and double-strand DNA breaks; inactivated by bleomycin hydrolase, which is scarce in lung and skin (fibrosis, hyperpigmentation).
1.Bleomycin slips into a pocket on its target.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Generic.
Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE search: bleomycin. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 1973 | Squamous cell carcinomas, Hodgkin and non-Hodgkin lymphoma, testicular carcinoma, malignant pleural effusion |
Read for the class this product belongs to (bleomycin) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Paclitaxel with antiretroviral therapy is the treatment to supply for advanced AIDS-associated Kaposi sarcoma in resource-limited settings; cheaper regimens are inferior.
Confirmation, by a different route from HD18, that the interim scan can safely direct de-escalation in advanced Hodgkin lymphoma, and that most of the toxicity of escalated BEACOPP can be avoided in the 84 per cent of patients who respond early.
Radiotherapy cannot be omitted in early-stage favourable Hodgkin lymphoma on the basis of a negative interim scan without a clinically relevant loss of tumour control. The scan is better at identifying who needs more than at identifying who needs less.
The interim scan should be used to intensify treatment in early Hodgkin lymphoma, not to withhold radiotherapy. The 99.0 per cent five-year progression-free survival in the scan-negative favourable group with combined-modality treatment is the number any radiotherapy-sparing strategy has to match.
The basis for four cycles of escalated BEACOPP as the German standard when the interim scan is negative, and the reason rituximab was abandoned as an addition to that regimen. The authors recommend the scan-guided strategy for all patients with advanced-stage disease.
BEP has been the backbone of curative chemotherapy for testicular cancer for nearly forty years.
Query for this drug: (TITLE:"Bleomycin" OR ABSTRACT:"Bleomycin" OR TITLE:"Blenoxane" OR ABSTRACT:"Blenoxane") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Bleomycin, not a curated reading list.
Shares Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide, Extragonadal germ cell tumour, GHSG HD10, Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group and the tags generic, who-essential.
Shares Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide, ACTG A5263/AMC 066: three chemotherapy regimens with antiretroviral therapy for advanced AIDS-associated Kaposi sarcoma in resource-limited settings, ACTG A5263/AMC 066, Yolk sac tumour of the testis, postpubertal type and the tags generic, who-essential.
Shares ACTG A5263/AMC 066: three chemotherapy regimens with antiretroviral therapy for advanced AIDS-associated Kaposi sarcoma in resource-limited settings, ACTG A5263/AMC 066, AHOD1331, AHL2011 and the tags generic, who-essential.
Shares AHOD1331, The cumulative dose that decides whether it comes back, AHL2011, PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study and the tags generic, who-essential.
Shares Choriocarcinoma of the testis, HIV-associated (AIDS-related) lymphomas, The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest, Testicular germ cell tumours and the tags generic, who-essential.
Shares Testicular germ cell tumours, Cytotoxic chemotherapy and the tags generic, who-essential.
Shares GETUG 13, The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest, Cytotoxic chemotherapy and the tags generic, who-essential.
Shares Cytotoxic chemotherapy and the tags generic, who-essential.